Karin Fahl Wader

Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B

Oddrun Elise Olsen, Karin Fahl Wader, Hanne Hella et al. · Cell Communication and Signaling · 2015 · 175 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +13

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

Olav Erich Yri, Dag Torfoss, Olav Hungnes et al. · Blood · 2011 · 168 citations

Medicine, Immunology, Oncology +11

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Mats Jerkeman, Christian Winther Eskelund, Martin Hutchings et al. · The Lancet Haematology · 2018 · 154 citations

Medicine, Oncology, Pharmacotherapy +12

Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up

Sandra Lockmer, Bjørn Østenstad, Hans Hagberg et al. · Journal of Clinical Oncology · 2018 · 56 citations

Medicine, Immunology, Oncology +10

Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin

Oddrun Elise Olsen, Karin Fahl Wader, Kristine Misund et al. · Blood Cancer Journal · 2014 · 54 citations · Full text

Medicine, Cancer Biology, Oncology +16